ATI RN
ATI Pharmacology Proctored Exam 2019
1. A healthcare professional is preparing to administer Filgrastim for the first time to a client who has just undergone a bone marrow transplant. Which of the following interventions is appropriate?
- A. Administer intravenously to prevent injury.
- B. Ensure that the medication is kept refrigerated until just prior to administration.
- C. Do not shake the vial; gently invert it to mix before withdrawing the dose.
- D. Discard the vial after removing one dose of the medication.
Correct answer: D
Rationale: When administering Filgrastim, only one dose should be withdrawn from the vial, and the vial should then be discarded to prevent any contamination or errors in dosing. It is crucial not to shake the vial but gently invert it to mix the medication before withdrawing the appropriate dose. Refrigeration is not required for Filgrastim; it should be stored at room temperature until just before administration. Choice A is incorrect because Filgrastim is typically administered subcutaneously, not intravenously. Choice B is incorrect as the medication should be stored at room temperature, not refrigerated, until administration. Choice C is incorrect as shaking the vial is not recommended for Filgrastim.
2. A nurse is caring for a client in an outpatient facility who has been taking Acarbose for type 2 Diabetes Mellitus. Which of the following laboratory tests should the nurse plan to monitor?
- A. WBC
- B. Serum potassium
- C. Platelet count
- D. Liver function test
Correct answer: D
Rationale: The correct answer is D, Liver function test. Acarbose can cause liver toxicity when taken long-term. Monitoring liver function tests periodically is essential to assess for any potential liver damage. Choices A, B, and C are incorrect because Acarbose does not directly impact white blood cell count, serum potassium levels, or platelet count.
3. When caring for a client with a wound infection, which action should the nurse perform first in the plan of care?
- A. Administer antibiotic medication.
- B. Obtain a wound specimen for culture.
- C. Review WBC laboratory findings.
- D. Apply a dressing to the wound.
Correct answer: B
Rationale: The priority action when caring for a client with a wound infection is to obtain a wound specimen for culture before initiating antibiotic therapy. This step is crucial to identify the specific microorganism causing the infection, allowing for targeted antibiotic treatment. Reviewing WBC laboratory findings and applying a wound dressing are important steps, but obtaining a wound specimen for culture takes precedence as it guides appropriate antibiotic therapy by identifying the causative organism.
4. A client is receiving treatment with vincristine. Which of the following findings should the nurse monitor?
- A. Hyperkalemia
- B. Neurotoxicity
- C. Neutropenia
- D. Bradycardia
Correct answer: B
Rationale: The correct answer is B: Neurotoxicity. Vincristine is known to cause neurotoxicity as an adverse effect due to its impact on the nervous system. Monitoring for neurotoxicity is crucial to detect any signs early. Choices A, C, and D are incorrect. Hyperkalemia is not a typical finding associated with vincristine. Neutropenia is a common side effect of chemotherapy but is not directly related to vincristine. Bradycardia is not a common adverse effect of vincristine.
5. A healthcare provider is preparing to administer Belimumab to a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare provider plan to take?
- A. Warm the medication to room temperature before administering.
- B. Administer the medication by IV bolus over 5 minutes.
- C. Dilute the medication in a 5% dextrose and water solution.
- D. Monitor the client for hypersensitivity reactions.
Correct answer: D
Rationale: Correct Answer: Monitoring the client for hypersensitivity reactions is crucial when administering Belimumab due to its known potential for severe infusion reactions and anaphylaxis. The healthcare provider should closely observe the client during the administration to promptly identify and manage any hypersensitivity reactions that may occur. Choice A is incorrect because warming Belimumab is not necessary before administration. Choice B is incorrect as Belimumab should not be administered as an IV bolus over 5 minutes; it should be given as an IV infusion over a longer duration. Choice C is incorrect as Belimumab should not be diluted in a 5% dextrose and water solution.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access